Skip to Content

ASCO GI 2025: Everolimus and Lanreotide Combo as a Breakthrough for Gastroenteropancreatic Neuroendocrine Tumors

The combination of everolimus, an mTOR inhibitor, and lanreotide, a hormone-blocking agent, has shown significant promise in extending progression-free survival (PFS) and improving objective response rates (ORR) for patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This first-line treatment strategy was particularly beneficial for patients with high-risk prognostic factors, showing better outcomes compared to everolimus alone.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top